InnoCare Pharma Limited (SHA:688428)

Market Cap	29.32B
Revenue (ttm)	1.22B
Net Income (ttm)	-280.26M
Shares Out	n/a
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,320,809
Average Volume	9,508,183
Open	25.94
Previous Close	25.90
Day's Range	25.74 - 27.33
52-Week Range	8.09 - 28.73
Beta	0.99
RSI	70.39
Earnings Date	Aug 20, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,089
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688428

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.